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detecting, measuring or determining analytes, or may be used 
for monitoring of physiological or other conditions. Devices 
of the present invention may comprise microheaters that are 
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METHODS AND DEVICES FOR THERMAL 
TREATMENT 
RELATED APPLICATIONS 
This application claims the priority of U.S. Provisional 
Patent Application No. 60/575,717, filed May 28, 2004, 
which is herein incorporated in its entirety. 
BENEFIT CLAIMS 
This application is a US National Stage of International 
Application No. PCT/US2005/019035, filed 31 May 2005, 
which claims the benefit of U.S. Provisional Application No. 
60/575,717, filed 28 May 2004. 
GOVERNMENT LICENSE RIGHTS 
The U.S. Government has a paid-up license in this inven-
tion and the right in limited circumstances to require the 
patent owner to license others on reasonable terms as pro-
vided for by the terms of Contract No. 8-ROI-EB00260-03 
awarded by the National Institutes of Health, and under Con-
tract No. F33615-02-C-l 160, awarded by the U.S. Air Force. 
TECHNICAL FIELD 
The present invention relates to methods using MEMS 
thermal treatment devices for increasing the permeability of 
barriers, for example by creating openings in barriers, such as 
skin, for providing active agents across the barriers, or for 
providing sites from which analytes can be retrieved and 
measured. 
BACKGROUND OF THE INVENTION 
2 
approaches to increase transdermal delivery have emphasized 
disruption of stratum corneum micro structure using chemical 
or physical methods. 
Conventional drug delivery using pills or injection is often 
not suitable for most protein or biotech active agents, DNA 
and other nucleic acid constructs, and other therapies cur-
rently proposed and envisioned. An attractive alternative 
would be transdermal delivery from a patch, which avoids 
degradation in the gastrointestinal tract and first-pass effects 
10 of the liver associated with oral delivery as well as the pain 
and inconvenience of intravenous injection. Transdermal 
drug delivery also offers the possibility to continuously con-
trol the delivery rate, in contrast to conventional methods that 
deliver a large, discrete bolus. These advantages have led to a 
15 multi-billion dollar market for transdermal patches used for 
smoking cessation (nicotine), hormone replacement (estra-
diol), and other indications. Despite these advantages, trans-
dermal drug delivery is severely limited by the poor perme-
ability of human skin; most drugs do not cross skin at 
20 therapeutic rates and only a dozen drugs have been approved 
by FDA for transdermal delivery since the first patch was 
introduced 25 years ago. The skin's barrier properties are due 
to the highly impermeable outer layer called stratum cor-
neum, which is 10-20 µm thick. Drugs that cross the stratum 
25 corneum barrier can generally diffuse to deeper capillaries for 
systemic distribution. For this reason, most approaches to 
increase transdermal delivery have emphasized disruption of 
stratum corneum microstructure using chemical or physical 
methods. Currently approaches exist to physically disrupt the 
30 stratum corneum using heating filaments or an array of elec-
trodes to generate Joule heating by passing a short, high-
current electric pulse. These devices are all powered by 
means of wires physically connected to an external DC or RF 
power supply. 
35 What is needed are methods and devices that can increase 
the permeability of barriers, such as skin, that do not require 
the physical connection of wires to link the power supply to 
the components that are causing the increase in permeability. 
Further, what is needed are methods and devices that provide 
40 for transdermal transfer of a greater variety of active agents. 
Transdermal delivery of certain drugs has been possible for 
many years. Transdermal drug delivery devices are generally 
laminated composites that include a pressure-sensitive adhe-
sive layer which may contains the drug and by which the 
device is attached to the skin and a backing layer which forms 
the outer surface of the device, which may form a reservoir for 
the drug, and which is impermeable to the drug. To date, 
commercial exploitation of transdermal drug delivery sys- 45 
terns has been limited to only a few specific active agents, 
because of the practical problems to be overcome. These 
problems include the solubility of the drug, the effect of the 
drug on the adhesive layer and delivery of the drug to the skin 
and through the stratum corneum and viable epidermis into 50 
the systemic circulation at a constant rate over a prolonged 
period. In addition, transdermal drug delivery devices must 
maintain their integrity during storage prior to use. 
Additionally, what is also needed are methods and devices 
that can aid in detecting and measuring analytes that are 
contained within a barrier, particularly skin or other mem-
branes. 
SUMMARY OF THE INVENTION 
The present invention comprises methods and devices 
using heat to increase the permeability of barriers, for 
example to create micropores in barriers, such as the inner and 
outer membranes of humans, animals, plants and other living 
organisms, or barriers used in industrial applications. For 
example, methods of the present invention comprise mini-
mizing the barrier properties of an inner or outer membrane, 
such as stratum corneum, using thermal treatment of the 
membrane to provide micropores through which active 
Transdermal delivery is difficult because of skin's highly 
impermeable outer layer called stratum corneum. The stratum 55 
corneum is 10-20 µm thick and, unlike other tissues in the 
body, contains "cells" filled with bundles of cross-linked 
keratin and keratohyalin surrounded by an extracellular 
matrix of lipids assembled in multiple bilayer structures. 
There are no blood vessels or nerves in stratum corneum. 60 
agents may be provided through the stratum corneum to the 
organism or from which one may controllably collect fluids or 
analytes from within the body to enable the monitoring or 
detection of these analytes. Methods comprise porating one 
or more selected areas of a barrier, thereby reducing the 
barrier properties of the barrier, using thermal treatment by 
microheaters. The microheaters are heated by ohmic or 
inductive heating. The microheaters may provide controlled, 
Below stratum corneum is the viable epidermis, which is 
50-100 µm thick and also contains no blood vessels, but has 
some nerves. Deeper still is the dermis, which measures 1-2 
mm thick and contains blood vessels, lymphatics and nerves. 
Drugs that cross the stratum corneum barrier can generally 
diffuse to the capillaries in the superficial dermis for absorp-
tion and systemic distribution. For this reason, most 
65 precise thermal ablation and create a micropore in the barrier. 
The microheaters may be used to create micropores in the 
barrier and may then be removed or remain in place. 
US 8,690,865 B2 
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The micropores formed in the barrier provide for methods 
for delivery of active agents through the barrier, such as 
transdermal delivery of drugs, nucleic acids, gene therapy 
molecules, or molecules that are not amenable to standard 
transdermal delivery. The micropores formed in the barrier 
can be used as sites for sampling fluids, monitoring, measur-
ing or detecting analytes from the interior of the barrier, such 
as for monitoring glucose in a human or animal. 
An aspect of the invention comprises thermal treatment 
devices decreasing the barrier properties of a barrier, for 10 
example by providing micropores in a barrier comprising a 
power supply component and a microheater component. The 
thermal treatment device may comprise both components in a 
single unitary device, wherein the components are in physical 15 
connection such as by a wire, or the components may be in 
separate units that may not be connected by physical attach-
ment, such as a wire. Wireless devices, comprising a power 
supply component not physically attached to the microheater 
component, may provide energy to the microheater compo- 20 
nent and activate the microheaters by inductive heating. 
An aspect of the invention comprises a microheater com-
ponent comprising one or more microheaters associated with 
a transdermal delivery patch comprising at least one active 
agent and a separate inductive energy supply component. In 25 
use of such a device, methods comprise applying the micro-
heater component comprising the transdermal delivery patch 
to the skin of a living organism, bringing the energy supply 
component close enough to the microheaters so as to heat the 
microheaters using inductive heating, forming micropores in 30 
the skin adjacent to the microheaters, removing the energy 
supply component, and allowing the microheater component 
comprising the transdermal delivery patch to remain associ-
ated with the skin and provide the active agent to the living 
organism. The microheaters of the present invention may or 35 
may not comprise rapid volume change materials. Such abla-
tion materials may be applied to a barrier prior to or simulta-
neously with contact by the microheaters. 
4 
FIG. 12 is a photomicrograph of a histological section of 
rat skin after micropore formation using a cone-shaped 
microheater. 
FIG. 13 is a schematic of heat transfer simulation (AN-
SYS) through skin by a heating element array. 
FIG. 14 shows transient thermal simulation of heat genera-
tion and cooling at the points indicated in FIG. 13. 
DETAILED DESCRIPTION 
The present invention comprises thermal treatment devices 
comprising inductive or ohmic heating elements and methods 
for making and using such devices. In general, the devices of 
the present invention comprise one or more microheaters, 
such microheaters can be provided to a barrier and when 
activated by particular frequencies, the microheater causes 
thermal treatment to remove an area of the barrier next to or 
near the end tip of a microheater. The device may comprise a 
unitary device comprising an energy supply component and a 
microheater component, comprising one or more microheat-
ers, where the energy supply component and the microheater 
component are electrically connected by a wire or other 
means. Alternatively, the thermal treatment device may com-
prise a dual component device comprising two separate com-
ponents, an energy supply component, and a component com-
prising one or more microheaters, which is referred to as the 
microheater component. The thermal treatment device may 
further comprise, but are not limited to, microneedles, analyte 
sensing or retrieval components, fluid sampling components, 
cooling components, or transdermal active agent delivery 
components, patches for delivery of active agents, each of 
which may be incorporated into either device, the unitary 
device or the dual component device. 
In the thermal treatment device, the microheaters may be 
activated by an ohmic heating element which has a high 
resistance point, or can be heated by inductive heating meth-
ods wherein the energy supply component supplies a modu-
lated alternating magnetic field from an excitation coil that 
produces eddy currents in the microheaters or in a structure 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. la-c are profile diagrams of microheaters, activated 
by ohmic power supply. 
FIG. 2a-e are profile diagrams of microheaters, activated 
by inductive heating power supply. 
40 attached to the microheaters, which causes the microheaters 
to increase inheat due to internal ohmic loss.An aspect of the 
invention comprises an energy source component that is sepa-
rate from and not physically connected to the component 
comprising the microheaters. An energy supply component 
FIG. 3 is a diagram of activation ofhollow post microheat-
ers by an inductive heating power supply component. 
FIG. 4 is a graph of the electrical resistance of the inductive 
heating element, RIH' over a frequency range of 50 kHz-2 
MHz. 
FIG. Sa-g are a schematic of the fabrication of a micro-
heater. 
FIGS. 6 a-dis a schematic of the fabrication of a transder-
mal patch incorporating microheaters on the surface. 
FIG. 7aj is a schematic of the fabrication of the micro-
heaters and attachment to a polymer backing. 
FIG. 8 is a profile diagram of a thermal treatment device 
comprising a cooling element. 
FIG. 9 is a graph showing the induction heating character-
istics of a hollow post microheater array. 
FIG. 10 is a photomicrograph of micropores formed in 
ablated human cadaver skin using the metallic cone-shaped 
microheaters. 
FIGS. lla and bare scanning electronmicrographs (SEM) 
of micropores formed inhuman cadaver skin using the hollow 
post microheater array. (a) is a top view, and (b) is an angled 
view of the same tissue as (a). 
45 comprises a basic induction power source which provides a 
required power output at a required power frequency, and an 
induction coil assembly. In general, an AC power supply 
sends alternating current through the coil, generating a mag-
netic field. When the microheaters are within the magnetic 
50 field, the magnetic field induces eddy currents in the micro-
heaters, generating known amounts oflocalized heat without 
physical contact between the microheater and the energy 
source. As used herein, activated means that the microheaters 
are heated by either ohmic heating element methods or by 
55 inductive heating methods. 
The microheaters of the present invention can be made 
from one or more materials that function to heat by ohmic or 
induction heating. An aspect of the invention comprises 
microheaters that function to heat by induction heating and 
60 may comprise metallic, nonmetallic or ceramic materials that 
provide heat when placed with the magnetic field of an induc-
tion coil. Magnetic materials resist the rapidly changing mag-
netic filed within the induction coil and the resulting friction 
creates heat, hysteresis heating, in addition to eddy current 
65 heating. A metal which offers high resistance is said to have 
high magnetic permeability. In most metals, eddy current loss 
is the dominant source of induction heating. When a conduc-
US 8,690,865 B2 
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tive material experiences alternating magnetic flux inside it, 
an electromotive force is induced in the material that causes a 
circulating current or eddy current, in accordance with Fara-
day's law of induction. This eddy current is converted into 
heat due to the Joule effect (i.e, resistive loss) in the conduc-
tive material. 
Microheaters of the present invention that are heated with 
inductive heating may be made from materials having a high 
relative magnetic permeability, and includes materials having 
a permeability from from a few tens to a few thousands. 
Additionally, microheaters of the present invention may com-
prise one or more materials having one or more Curie points. 
Upon reaching a set temperature, the microheater materials 
transition from magnetic to paramagnetic and no heating 
beyond the set temperature can occur. By changing the per-
cent of constituent elements in an alloy or other material, the 
Curie point may be changed to a desired temperature. Devices 
of the present invention may comprise multiple microheaters 
wherein some microheaters are made from a material having 
one Curie point and other microheaters are made from a 
material having a different Curie point. 
6 
Manual or computer software means may be used to turn the 
power on or off, change the frequency or provide a sweep or 
step up of frequencies to affect the microheater component. 
A microheater of the present invention comprises a thermal 
member comprising a base end and a tip end. The tip end is 
intended to contact the barrier directly or to contact ablation 
materials present on the barrier. The base end of the micro-
heater is the end opposite from the tip end, and in certain 
fabrication methods, may form an integral part of the array 
10 structure that connects an array of microheaters. The base end 
may be in contact with insulation materials, with a transder-
mal patch, or with analyte detecting means. Microheaters of 
the present invention may be made from one or more mate-
rials that are capable of being heated and transferring the heat 
15 to the surrounding environment. The thermal member may be 
made from a single type of metal, layers of metals, conductive 
oxides, conductive polymers or alloys, and include, but are 
not limited to, nickel, nickel-iron, ferromagnetic materials, 
copper, NiCu, PdCo, gadolinium-silicon-germanium alloy, 
20 aluminum, ceramic materials, electrodeposited or vapor-de-
posited gold, platinum, or palladium outer layer coating of 
nickel, nickel-iron or a magnetic stainless steel-type alloy 
(e.g. 400-series ), indium tin oxide, lanthanum strontium 
cobalt oxide, and aluminum doped zinc oxide. The micro-
Microheaters of the present invention may also be charac-
terized by the response to one or more frequencies of the 
alternating magnetic field. For example, in many cases, as the 
frequency is increased the amount of energy dissipated in the 
material and therefore, the heating rate, is also increased. The 
microheaters of the present invention may comprise one or 
more materials or geometries that are differently affected by 
one or more frequencies of the alternating current. This can be 
achieved for example, by making microheaters of differing 
electrical conductivities, magnetic permeabilities, coercivi-
ties, Curie temperatures, or even geometry, e.g., through the 
use of magnetic laminations. For example, one portion of the 
microheater heats to its maximum at one range of frequen-
cies, while another portion of the microheater heats to its 
maximum at a different range of frequencies. Multiples of the 
microheaters of the present invention may comprise some 
microheaters that heat to the maximum heat at one range of 
frequencies, while different microheaters heat to the maxi-
mum heat at a different range of frequencies. Frequencies 40 
used in the present invention are from about 50 Hz to 1 MHz 
with high permeability materials and are in a microwave 
range, from about 1 MHz to about 300 GHz with good elec-
trical conductors and extended to all ranges in between. The 
present invention comprises microheaters that comprise 
materials that are heated by methods of frequency selective 
heating and may also comprise materials that have tempera-
ture dependent permeability. 
25 heater may open or enclosed spaces, in that there is a space 
between portions of the thermal member or between two 
adjacent thermal members, or the thermal member may be a 
shell structure, enclosed but having a hollow interior space. 
For example, the loop shape of FIG. 2d is an example of an 
30 open spaced microheater with space between portions of the 
thermal member, and the hollow post microheater of FIG. 3 is 
an example of a space between two adjacent thermal mem-
bers. Such spaces may or may not be used to contain ablation 
materials. As used herein, microheaters of the present inven-
35 ti on may or may not be in physical contact with rapid volume 
change materials. Such physical contact may be by coating, 
applying or in some way associating the tip end, or an open or 
enclosed space of a microheater with one or more rapid vol-
ume change materials. 
Microheater components or individual microheaters of the 
present invention may also comprise an insulating portion. 
The insulating portion acts as an insulator and prevents the 
transfer of heat from the heated portion of a microheater or 
from one or more microheaters. The insulator can be made of 
45 any material that provides thermal insulation, and is generally 
a nonconductor or nonmagnetic. Insulators of the present 
invention include, but are not limited to, Mylar, Kapton (poly-
imide ), polyurethane, liquid crystal polymer, and epoxy. 
An aspect of the invention comprises the distance between 
the power supply component and the microheater component. 
Using ohmic heating, the power supply is in electrical wire 
connection with the microheater component.Using inductive 
heating, the power supply component is not electrically con-
nected, through wires, to the microheater component, but 
may be placed in physical contact with the microheater com-
ponent if necessary. The distance between the power supply 
component and the microheater component relates to the 
coupling efficiency, which is the proportional relationship 
between the amount of current flow in the microheaters and 
Multiples of individual microheaters may be used. As used 
50 herein, multiples of microheaters means more than one 
microheater used in a microheater component. Each micro-
heater is a separate element and thus, can be positioned at any 
location. The multiples of microheaters may be arranged in 
any desired pattern or array in or on the microheater compo-
55 nent. The multiples of microheaters may be arranged such 
that microheaters having the same characteristics, such as 
heating frequency or Curie point, are arranged together to 
provide an area of the microheater component that heats 
the distance between the microheaters and the coil. Close 60 
under one set of conditions, and another area of the micro-
heater component comprises microheaters having a different 
characteristic so that in operation, one area under one set of coupling generally increases the flow of current and thus, 
increases the amount of heat produced in the microheater. The 
power supply component may be a distance from the micro-
heater component of from physical contact to inches to feet 
apart. The power supply may be manually operated or may be 65 
operated by a controller, either remote to the power supply 
component or may be a component of the power supply. 
conditions would heat and another area would not. The mul-
tiples of microheaters may be arranged so that microheaters 
having one characteristic are alternated with microheaters 
having a different characteristic, such as heating frequency or 
Curie point. The microheaters may be in contact with one 
another by a structure such as a plate attached to the base ends 
US 8,690,865 B2 
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of the microheaters, or by wires, or in contact within a specific 
group of microheaters, or may be a stand alone microheater. 
The activation of one or more microheaters may comprise 
heating the plate or other structure attached to one or more 
microheaters in addition to activating the microheaters. 
The microheaters may be made in any shape desired for the 
specific application. Microheaters can be designed with dif-
ferent materials and geometries to produce different thermal 
responses. For example, the shape of the microheaters may be 
a disk, a cone, a donut or loop, or other geometries, and the 10 
size can vary from less than 1 micron to hundreds of microns. 
Other shapes contemplated are shown in the figures herein, 
including FIGS. 2a-e and FIG. 3. FIG. la-c show diagrams of 
thermal treatment devices of the present invention compris-
ing an ohmic energy supply component in electrical connec- 15 
tion withmicroheaters of various shapes. FIGS. la-c show 10 
the power supply, 20 an electrical resistance microheater, and 
30 an in-plane substrate, 40 a three dimensional substrate, 50 
microneedle microheaters. 
The energy supply component and the microheater com- 20 
ponent may be used in various applications where thermal 
treatment, such as to alter barrier permeability or to form 
micropores in a barrier is needed or desired. For example, 
thermal treatment to form micropores in a covering or barrier 
of a living organism allows for transdermal delivery of active 25 
agents into humans, animals, or plants. The thermal treatment 
devices may be used to provide thermal treatment to form 
micropores to any barrier of a living organisms, including 
outer barriers such as skin or mucous membranes, or inner 
coverings such as linings, membranes, or organ surfaces. 30 
Thermal treatments can increase barrier permeability, such as 
provide micropores, that are used in transport of active agents 
into an organism or micropores and treated sites can provide 
for retrieval of fluids contained by or within the barrier, and/or 
for detection or measurement of analytes. Examples of trans- 35 
dermal transport across outer skin surfaces of animals are 
discussed herein, but the invention contemplates other appli-
cations of transport in animals and plants, and includes indus-
trial uses and other applications of the present devices. As 
used herein, thermal treatment comprises using activated 40 
microheaters or activated microheaters in combination with 
ablation materials to increase the permeability of a barrier, for 
example by forming micropores in a barrier. 
An aspect of the present invention comprises a wireless 
induction heating device for generating micron-scale pores in 45 
the skin of a human or animal to increase the permeability of 
the skin, and provide active agents through the micropores 
using conventional transdermal patch delivery methods. The 
separation of the power supply component and the micro-
heater component provides design flexibility and allows for 50 
integration ofmicroheaters into transdermal patches. FIG. 3 
shows a schematic diagram of the inductive heating system, 
including a power supply component comprising an AC 
power source 170 and an excitation (induction) coil 140, and 
8 
example, creating micropores in a barrier. The microheaters 
of the devices create pores with small pore size, from sub-
micron to micron sized pores, and can be used to control the 
micropore geometry. When used to create micropores in bar-
riers such as skin, the reduction in pore size aids in minimiz-
ing infection and pain. The devices of the present invention 
increase the integration density of microheaters by increasing 
the number microheating spots in the unit area treated by 
adopting advanced microelectromechanical systems 
(MEMS). The devices of the present invention may increase 
skin contact by fabricating the microheaters on the top of 
3-dimensional structure with MEMS technologies. The 
present invention may use microneedle structures as micro-
heaters, which may aid in control of the depth of the ablated 
area, or the devices of the present invention may be used to 
create micropores into which microneedles are inserted. For 
example, micropores are formed using the devices of the 
present invention as a pretreatment step for removing barri-
ers, for example stratum corneum, having a high Young's 
modulus. The thermal treatment devices of the present inven-
tion may be used as pretreatment devices for any application 
where reduction in the barrier properties of a barrier, or where 
increased permeation of the barrier is desired. For example, 
the thermal treatment devices of the present invention may be 
used to increase the permeability of a barrier, for example, by 
forming micropores in a site on a barrier, referred to as the 
pretreatment site, and a patch comprising active agents may 
be applied to the pretreated site for transfer of the active 
agents through the pretreated site of the barrier. Additionally, 
the thermal treatment devices of the present invention may be 
used to increase the permeability of a barrier, for example, by 
forming micropores in a site on a barrier, referred to as the 
pretreatment site, and fluids, either leaking into the micropore 
or in the barrier, or on the opposite side of the barrier, may be 
sampled, or analytes in the fluid may be monitored, detected 
or analyzed. 
The microheaters of the present invention may form 
micropores that are of any desired size, from less than 1 
micron to a few hundred microns, and size is dependent on the 
size of the surface of the microheaterthat is in contact with the 
barrier. The microheaters may be heated to desired tempera-
tures that create micropores in a barrier, such temperatures 
ranging from a cooled temperature, room temperature, or an 
unheated state, to over 400° C., or any temperature necessary 
to raise the ablation materials on a barrier to a temperature at 
which the ablation of the barrier occurs and the micropore is 
formed. For example, when the barrier is stratum corneum of 
a human, the temperature of the area of the skin in contact 
with the surface of the microheater is elevated to greater than 
100° C. 
FIG. 2a-e show examples of thermal treatment devices of 
the present invention wherein the microheaters are activated 
by inductive heating power supply component. FIG. 2a-e 
show diagrams of thermal treatment devices comprising a 
power supply component that is not connected to the micro-
heater component and which activates the microheaters by 
inductive heating. FIG. 2a shows 30 in-plane substrate, 80 
microheater and 70 the magnetic field produced by the power 
supply component. FIG. 2b shows 40 a three dimensional 
substrate, and 70 and 80 as above. FIG. 2c shows 60 micron-
eedle microheaters, and 30 and 70 as above. FIG. 2d shows 
100 a loop microheater, and 30 and 70 as above. FIG. 2e 
shows 110 hollow pointed tip post microheaters and 30 and 70 
as above. An aspect of the invention comprises positioning 
a microheater component comprising microheaters. The 55 
wireless energizing ofa magnetic field is indicated as 120, the 
base plate structure of the microheater 150 is attached to the 
hollow posts 130, and PDMS 160 provides insulation for the 
microheater. 190 is the barrier, such as stratum corneum, and 
180 is the micropore formed in the barrier. In general, a power 60 
supply component comprises an excitation coil, a radiofre-
quency generator and amplifier and control logic. The micro-
heaters are separate from the power supply component and 
are adjacent to a barrier, in this case, the stratum corneum of 
human or animal skin. 65 the microheaters on an insulating substrate, on or in a trans-
dermal patch, and the microheaters are activated by a separate 
inductive power supply component unit. Tests have shown 
The thermal treatment devices of the present invention are 
used to decrease the barrier properties of a barrier, by for 
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that with microheaters activated by inductive heating, the 
temperature of a microheater surface increases along with the 
induction time, and the tip end of the microheater metal shell 
shows a faster heating response than does the basement or 
side walls of the metal shell of the microheater. 
Examples of microheaters for use with inductive heating 
power supply components of the present invention include a 
metallic cone structure of tip diameter of SO µm, base diam-
eter of 400 µm, metal shell thickness of 50 µm, and height of 
2 mm; and an array ofhollow metallic posts, with an inner tip 
diameter of 100 µm, metal thickness of30 µm, and post height 
of 400 µm. Fabrication of the metallic cone structure included 
laser drilling polymer sheets to form molds containing coni-
cally tapered holes, then electrodepositing a thin conductive 
metal seed layer onto the mold, and electroplating nickel onto 
the mold to form the final shell cone-shaped structures. Only 
the small tip area is intended to contact the barrier, thus 
providing a small, controlled porated area of the barrier. 
10 
Nickel 240 is electroplated on the seed layer, and the protrud-
ing SUS is polished away (Sd). Polydimethylsiloxane 
(PDMS) 160 is applied evenly to the structure (Se). Again, 
RIE is performed to reveal the tip of the electroplated posts 
(Sf). Finally the entire microheater array is released from the 
dummy substrate (Sg). The microheater array was formed as 
a 20x20 array ofhollow posts with a base plate. The base plate 
in this array forms a connection between all of the microheat-
ers, and when exposed to the power supply component and is 
10 
activated, generates the induction (eddy current) heat and 
transfers the heat to the hollow posts. The PDMS layer pro-
vides an insulation layer between the base plate and the bar-
rier. When the microheater component is heated, there is no 
15 transfer of heat from the base plate to the barrier, and the only 
heat transferred to the barrier is, in this example, at the tip end 
of hollow posts of the microheater. The hollow posts can be 
made of nickel, which has a high relative magnetic perme-The hollow metal cone shaped microheaters were charac-
terized to assess their electrical performance. According to 
well-established inductive heating theory, the inductive heat- 20 
ing power of the heating elements is represented as an AC 
resistance, i.e., the real part of the impedance, of the excita-
tion coil. Therefore, by measuring the portion of the AC 
resistance of the excitation coil attributable to the heating 
elements, the heating power delivered to the heating elements 
can be estimated. 
ability. 
Power supply components may be made by techniques 
known to those skilled in the art. For example, the excitation 
coil can be fabricated by conventionally winding conductor 
coils on optimally-shaped hollow polymer cores, optionally 
incorporating flux-guiding magnetic material. Size, fre-
25 quency and coil current can be optimized for the particular 
application. 
The AC resistance of the inductive heating system (RIH) is 
calculated as the difference between the resistance of the 
The present invention comprises a transdermal drug deliv-
excitation coil with the heating element inside and the resis-
tance of the excitation coil without the heating element inside. 30 
The AC resistance of the excitation coil both with and without 
ery device comprising a power supply component and a 
microheater component comprising a transdermal patch com-
prising at least one active agent and one or more microheaters 
in an array. The microheater component is an integral to the 
the heating elements inside was measured and the RIH was 
calculated. FIG. 4 indicates that RIHincreases with increasing 
frequency, indicating that heating power also increases with 
increasing frequency even though the input current of the 
excitation coil remains the same. The inductive heating power 
of this system was then determined as (I,nput)2 RIH" Using data 
in FIG. 4 shows that when the input current to the coil is 1 A 
(Amp), the resultant heating power on the hollow cone is 
approximately 1 W (watt) and SW at 200 kHz and 2 MHz, 
respectively. 
To characterize the thermal output of inductive microheat-
ers, the temporal evolution of the surface temperature of 
hollow metal cones was measured after an excitation pulse 
using an infrared camera with spatial resolution of 5 µm. The 
IR camera image displayed the surface temperature distribu-
tion and indicated a large temperature increase up to 132° C. 
on two microheaters imaged. These results are for a highly 
non-optimized inductive heating system. With optimization 
of components, different results are seen. 
An example of methods for fabrication of a post type 
microheater is shown in FIG. S. In general, microheaters can 
be fabricated using micromachining techniques by a process 
which consists of first patterning the shape of the structures 
onto a polymer mold using lithography and then electroplat-
ing metal into the mold to generate the metal heating ele-
ments. Using such methods, microheaters with dimensions 
from 1 µm to 1 mm can be made. FIG. Sa-g shows steps for 
making a microheater of the present invention. Photosensitive 
or photopattemable epoxy polymer SUS (Microchem, Inc.) 
200 is patterned to form an array of posts on a dummy sub-
strate (glass) 220 and an electroplating seed layer of Ti/Cu 
210 is deposited on it. (Sa) Polymethylmethacrylate 
(PMMA) 230 is applied to the posts (Sb). Reactive ion etching 
(RIE) is performed to expose the top portion of the posts, and 
the exposed seed layer is removed by wet-etching (Sc). The 
remaining PMMA is removed by an organic solvent rinse. 
transdermal patch such that when the microheaters are 
heated, the barrier, such as skin or membrane of a human or 
animal, that the microheaters are touching is ablated, and the 
35 active agent of the transdermal patch enters the micropore in 
the barrier and transits the barrier, such as entering the human 
or animal through the micropores that are formed. A fabrica-
tion method for the transdermal drug delivery device is shown 
in FIGS. 6a-c, and also in greater detail in FIG. 7aj. FIG. 6a 
40 shows an adhesive layer 2SO in contact with an insulating 
layer 260 such as a polyester Mylar, in contact with an adhe-
sive layer 270 all of which are attached to a patch 280 with an 
active agent contained within the body of the patch. FIG. 6b 
shows the attachment of microheater 290 to the adhesive layer 
45 2SO of the patch. FIG. 6c shows the microheater component 
comprising a patch, such as a transdermal patch, and micro-
heaters disposed on an outer surface. FIGS. 7ajshow fabri-
cation steps for a microheater component comprising a poly-
meric patch andmicroheaters. FIG. 7a shows a glass substrate 
50 310 with an electroplated seed layer of gold or nickel 300 
using a vacuum deposition process. FIG. 7b shows photore-
sist 320 patterned on the seed layer. The metallic microheater 
array 240 is electroplated through the photoresist mold, as 
shown in FIG. 7c. FIG. 7d shows the photoresist removed 
55 with acetone. A polymer patch 330 with adhesive is allied to 
the electroplated microheater array on the glass, see FIG. 7e, 
and the array is released from the substrate in FIG. 7/ A 
transdermal patch, such as those known in the art, containing 
the active agent is covered with an impermeable polymer 
60 layer, which does not transfer active agents, on the back and 
sides, of the transdermal patch. The transferring surface has 
an adhesive layer, generally for attaching the patch to a recipi-
ent. Pre-cut polyester, such as Mylar, with a thickness of 100 
µmis placed on the adhesive layer. Mylar is an example of a 
65 thermally insulating material that provides good thermal iso-
lation with a relatively thin layer. Microheaters are aligned 
and transferred to the transdermal patch by adhesive onto the 
US 8,690,865 B2 
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Mylar layer, resulting in an integrated transdermal patch com-
prising microheaters. Pores in the insulating layer may be 
used to allow for movement of the active agent contained in 
the transdermal patch from the patch to the skin. Alterna-
tively, the Mylar may be present as an insulator only at the 
contact area with the base end individual microheaters. 
Transdermal patches are well known in the art and the 
present invention includes all forms of transdermal delivery 
12 
sychotics; antipyretics; antispasmodics; anticholinergics; 
sympathomimetics; xanthine derivatives; cardiovascular 
preparations including potassium and calcium chamiel block-
ers, beta-blockers, alpha-blockers, and antiarrhythmics; anti-
hypertensives; diuretics and antidiuretics; vasodilators 
including general coronary, peripheral and cerebral; central 
nervous system stimulants; vasoconstrictors; cough and cold 
preparations, including decongestants; hormones such as 
estradiol and other steroids, progesterone and derivatives, 
testosterone and derivatives, including corticosteroids; 
angiogenic agents, antiangeogenic agents, hypnotics; immu-
nosuppressives; muscle relaxants; parasympatholytics; nico-
tine, psychostimulants; sedatives; tranquilizers, ionized and 
nonionized active agents, and compounds of either high or 
of active agents comprising an incorporated microheater 
component including, but not limited to, transdermal devices 10 
such as devices with a fill and seal laminate structures, periph-
eral adhesive laminate structures and solid state adhesive 
laminate structure or devices with the active agent incorpo-
rated in the adhesive. As used herein, a patch functions in the 
same mamier as a transdermal patch, but a patch can be used 15 low molecular weight. The active agents may have local 
effects, such as providing for a local anethesia, or may have 
systemic effects. The present invention is contemplates the 
mode of delivery of active agents, and is not limited by the 
particular active agents delivered. Other methods for increas-
on any barrier to supply compositions such as active agents to 
the barrier, but is not limited to epidermis or dermis of human 
or animal skin as the barrier, as may be understood for trans-
dermal patch. Transdermal drug delivery is discussed in gen-
eral in Cleary, G. W., "Transdermal Drug Delivery", Cosmet- 20 ing transport of molecules across skin or other membranes 
may be used with the present invention such as microneedles, 
ultrasonication or electroporation techniques. 
ics & Toiletries, Vol. 106, pgs. 97-109, 1991 which is 
incorporated herein by reference. Transdermal devices for the 
delivery of a wide variety of biologically active agents have 
been known for some time and representative systems which 
utilize rate controlling membranes and in-line adhesives are 
disclosed in U.S. Pat. Nos. 3,598,122; 3,598,123; 3,742,951; 
4,031,894, 4,144,317; 4,201,211 and 4,379,454 which are 
incorporated herein by reference. Such devices generally 
comprise an impermeable backing, a drug or active agent 
reservoir, a rate controlling membrane and a contact adhesive 
layer which can be laminated or heat sealed together to pro-
duce a transdermal delivery device. U.S. Pat. Nos. 5,013,293; 
5,312,325 and 5,372,579 disclose an electrolytic transdermal 
patch provided with a current oscillator for the periodic deliv-
ery of an active agent, and are herein incorporated by refer- 35 
ence. Other methods for control of transport are taught in 
Smith, et al. 1995, and Bronaugh, et al., 1999. The driving 
force for transport may include gradients in concentration, 
chemical potential, pressure, osmotic pressure, voltage and 
other gradients. Methods may include diffusion, osmosis, 40 
convection, electrophoresis, electrosmosis, convective dis-
persion and other mechanisms. As shown herein, these and 
other transdermal delivery devices can incorporate one or 
more microheaters for thermal treatment of the skin to aid in 
the transdermal flux rate of the active agent and reduce the 
barrier properties of the skin or other membranes. 
Though not wishing to be bound by any particular theory, 
it is believed that the micropores formed by the heat delivered 
25 by the microheater to the area of the barrier immediately 
adjacent to or touching the tip of a microheater are formed due 
to the heat from the microheater causing a rapid expansion or 
a rapid change in volume of one or more substances present. 
Such substances that undergo this change in volume and aid 
30 in formation of the micropore are referred to herein as abla-
tion material or ablation materials. Ablation material includes 
any liquid, gel, solutions or multiphase materials, or solid, 
alone, or in combination with other liquids, gels, solutions or 
multiphase materials or solids in chemical mixtures or reac-
tions, that, in response to the heat provided by the micro-
heater, undergoes a volume expansion, in 1 microsecond to 1 
second, that is sufficiently extensive to physically remove at 
least a portion of the barrier. Ablation materials having vapor-
ization temperatures, as in those materials that vaporize at 
temperatures, of from about 24° C. to about 200° C. are 
useful. Ablation materials may be in physical contact with a 
microheater, or may be provided in a separate composition to 
a barrier. 
Alternatively, the microheaters of the present invention 
45 may alter or decrease the barrier properties of the barrier, or 
increase the permeability of the barrier, by heating effects on 
materials present. For example, heating of the skin may liq-
uefy oils or fats in the skin to alter the barrier properties of the 
skin. The present invention comprises methods of providing 
As used herein active agent means a pharmaceutical or 
biotechnological compound or construct that induces a bio-
logical or pharmacological effect on an organism; and can 
also be a compound, molecule, chemical, or biological con-
struct, that provides a physical or chemical change to an 
existing condition. 
The methods and devices of the present invention allow for 
the delivery of active agents that may or may not currently be 
delivered using transdermal delivery patches. The delivery of 
many agents are limited by the barrier functions of skin or 
membranes of organisms. Active agents of the present inven-
tion include, but are not limited to, agents for gene therapy, 
nucleic acids, viruses, antigens, immunogens, chemical or 
biological materials or compounds that induce a desired bio-
logical or pharmacological effect, antiinfectives such as anti-
biotics and antiviral agents; analgesics and analgesic combi-
nations; anorexics; antihelminthics; antiarthritics; 
antiasthmatic agents; anticonvulsants; antidepressants; 
antidiabetic agents; antidiarrheals; antihistamines; antiin-
flammatory agents; antimigrainepreparations; antinauseants; 
antineoplastics; antiparkinsonism drugs; antipruritics; antip-
50 ablation materials to the environment to ablate sites, or form 
micropores, in a barrier site adjacent to or touching the tips of 
microheaters. Such ablation materials may be provided to the 
barrier prior to application of the microheater component to 
the barrier, may be provided simultaneously with application 
55 of the microheater component to the barrier, or may be physi-
cally associated with the microheater component or the indi-
vidual microheaters. For example, solutions, multiphase liq-
uids or gels comprising ablation materials may be provided to 
the barrier prior to the application of the microheater compo-
60 nent to the barrier. Upon heating of the microheaters, the 
liquid or gel, or ablation materials comprised by the liquid or 
gel, are affected by the temperature of the microheaters, 
undergo a rapid volume change, the barrier is affected and at 
least one micropore is formed in the barrier. Another example 
65 of providing ablation materials comprises providing hydrated 
salts, for example, coated on the tip ends of the microheaters 
or coated within a hollow portion of a microheater, and when 
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the microheater is heated, the solid is affected by the tempera-
ture of the microheater, undergoes a rapid volume change, the 
barrier is affected and the micropore is formed in the barrier. 
Compounds or chemical mixtures that participate in chemical 
reactions to undergo rapid volume changes in response to the 
heat from the microheater may be provided to the barrier 
through these methods and provide ablation materials for 
affecting the barrier and forming the micropore in the barrier 
when the microheater is heated. Such compounds or chemical 
mixtures may be provided directly to the barrier or associated 10 
on or within a hollow portion of a microheater. For example, 
ablation materials may be in a solid form and found within a 
hollow portion of microheaters such as those shown in FIGS. 
2d-e, and 10. Examples of such ablation materials include, 
but are not limited to, ablation materials comprise liquids, 15 
gels or solids, comprising hydrophobic liquids, hydrophilic 
liquids, water, ethanol, methanol, organic compounds, alco-
hols, ketones, aldehydes, amines, ethers, esters, oils, paraf-
fins, fatty acids, salt hydrates, including but not limited to 
calcium hydrates, sodium sulphate decahydrate, sodium 20 
phosphate dodecahydrate, calcium chloride hexahydrate and 
sodium thiosulfate pentahydrate, mixtures or combinations. 
Poration of the barrier may also be accomplished by affecting 
the barrier by contacting a selected area, up to about 1000 µm 
across, of the barrier with a microheater such that at least 25 
some of the temperatures oflocalized ablation materials, such 
as tissue-bound water, oils, sebum, cellular debris, and other 
substances in the selected area are heated to a point where one 
or more of the substances undergoes a rapid volume change 
and the selected area of the barrier is affected, and a 30 
micropore is formed. 
As used herein "poration," "microporation," or a similar 
term means the formation of a small hole or pore in a barrier 
in a selected area of the barrier which lessens the barrier 
properties of the barrier to the passage of analytes from the 35 
side of the barrier opposite from where the microheaters are 
contacting the barrier, for detection or measurement of ana-
lytes, or the passage of active agents across the barrier. 
Micropores formed are generally no larger than about 1 mm 
in diameter, and more preferably no larger than about 100 µm 40 
in diameter, and will extend as far into the barrier as desired, 
but at least to a depth where the barrier properties of the 
barrier are disturbed, without adversely affecting underlying 
or nearby structures. 
As used herein "ablation" means the controlled removal of 45 
an area of the barrier, due to the actions of the ablation 
materials and the activated microheater, or the activated 
microheater alone contacting the barrier at the selected site. 
Though not wishing to be bound by any particular theory, it is 
believed that the heat provided by the microheaters, option- 50 
ally in combination with added ablation materials, leads to the 
barrier or components of the barrier to be rapidly expelled 
from the contact site. 
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methods of the present invention comprise increasing the 
transdermal flux rate of an active agent across the stratum 
corneum of a human or animal, comprising using a thermal 
treatment device comprising a power supply component that 
is not physically connected to a microheater component, and 
a microheater component comprising a transdermal patch 
wherein one or more microheaters are present on or in one 
surface of the transdermal patch such that application of the 
transdermal patch to the stratum corneum of a human or 
animal brings the microheaters in contact with the stratum 
corneum, activating the microheaters, increasing the perme-
ability of the stratum corneum by porating the stratum cor-
neum by forming one or more micropores in specific sites in 
the stratum corneum without causing widespread damage to 
the stratum corneum or underlying dermal layers, reducing 
the barrier properties of the stratum corneum to the transder-
mal flux rate of the active agent; and providing the porated 
stratum corneum with a composition comprising an effective 
amount of the active agent such that the transdermal flux rate 
of the active agent into the body is increased. 
As used herein, "transdermal flux rate" is the rate of pas-
sage of any analyte from one area or surface of a barrier to 
another area or surface, or the rate of passage of any active 
agent from one area or surface of a barrier to another area or 
surface. This term is commonly understood by those skilled 
in the art, and its usual and customary meaning is intended 
herein. As used herein, "analyte" means any chemical or 
biological material or compound which may be measured, 
determined, monitored, and/or analyzed in order to gain 
information, or determine the status, related to the object or 
organism that is the source of the analyte. Glucose is an 
example of an analyte, and other examples of analytes 
include, but are not limited to, sodium, potassium, bilirubin, 
urea, animonia, calcium, lead, iron, lithium, salicylates, hor-
mones, and the like. 
Optionally, the methods of the present invention may be 
preceded or followed by methods for cooling the area of the 
barrier, such that the methods may further comprise cooling 
the selected area of barrier and adjacent areas with cooling 
means such that said selected area and adjacent areas are in a 
selected precooled, steady state, condition prior to poration. 
An example of incorporation of a cooling component is seen 
in FIG. 8. FIG. 8 is a diagram of a thermal treatment device 
with a power supply 10, a Peltier cooler 340, in combination 
with the in-plane substrate 30, and microheaters 20. 
Methods of the present invention comprise thermal treat-
ment of a barrier with the devices described herein such that 
interstitial fluid, other bodily fluids, or fluids retained by the 
barrier, exudes from or forms in the micropores, collecting or 
sampling the fluid in the micropore, and analyzing, measur-
ing or detecting, one or more analytes in the collected fluid. 
Collecting or sampling means include, but are not limited to, 
a vacuum or absorption member, may be applied to the Methods of the present invention comprising increasing 
the transdermal flux rate of an active agent across a barrier, 
such as the skin or membranes of an organism, comprise 
using the devices described herein to increase the permeabil-
ity of the barrier by applying a microheater component to a 
barrier, activating the microheaters in the microheater com-
ponent, porating the barrier by forming one or more 
micropores in specific sites in the barrier without causing 
widespread damage to the barrier or underlying structures, 
reducing the barrier properties of the barrier to the transder-
mal flux rate of the active agent; while contacting the porated 
specific area with a composition comprising an effective 
amount of the active agent such that the transdermal flux rate 
of the active agent into the body is increased. For example, 
55 microporated area to remove the fluids. Alternatively, the 
fluid and any analytes therein may be analyzed, measured or 
detected in situ in the micropore, without removal of the 
fluids. Methods for determining or measuring analytes are 
known in the art, and include, but are not limited to color 
60 change assays, immunoassays, specific binding partner 
assays, and other tests for analytes. Following such analysis, 
measurement or detection methods, one or more micropores 
can be sealed by reactivating the microheater using the power 
supply component to cause fluid remaining in the micropore 
65 to coagulate. Alternatively, the devices of the present inven-
tion can be used to reopen pores that begin to close by reac-
tivating the microheaters. These reactivations are accom-
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plished by providing the energy supply component within a 
range of distance to the microheaters so as to activate the 
microheaters. 
The methods of the present invention contemplate that 
microheater components may be applied, stuck by adhesives, 
attached, bound, wrapped within a dressing, or by other 
means of attaching the component, for a limited time period 
to a barrier. For example a transdermal patch microheater 
component may be applied the skin or membranes of a human 
16 
devices and methods separate cheap and disposable micro-
heaters from a reusable power source, thereby, providing 
economic, sanitary, and convenient microablation methods. 
Independent microheaters or arrays of microheaters embed-
ded within a transdermal patch, can facilitate use of well-
established transdermal technology and manufacturing, as 
well as providing a small, cosmetically acceptable device. 
The simplicity of the devices and methods of the present 
invention make use by elderly, pediatric, veterinary and other 
patients more straightforward. 
Further, the wireless heating technology of the present 
invention has other applications. For example, the on-de-
mand, wireless heating may be used to activate release of drug 
15 in a pulsatile manner, of critical importance to drugs such as 
hormones. The wireless nature also facilitates communica-
or animal for 0.5 minutes to 24 hours, for 1-6 days, for 1-3 10 
weeks, for months at a time. Other microheater components 
may be applied to a barrier for longer periods, depending on 
the intended uses. The individual microheaters in the micro-
heater components of the present invention may be activated 
once to provide heat transfer to specific sites on the barrier or 
may be activated multiple times, including from 1 to 1000 
times, from 1-20 times, from 5 to 50 times, and all times in 
between. The microheater component may remain in the 
same site on the barrier or may be moved to different sites, 
depending on the intended use. The present invention con- 20 
templates one or more activations of a microheater to form 
and/or maintain micropores. For example, one activation of a 
microheater, comprises heating the microheater to its prede-
termined temperature, and allowing it to return to a cooler 
temperature or to a preactivation temperature. Such activation 25 
may be accomplished by a power supply component provid-
ing ohmic heating or a power supply component providing 
inductive heating. The activation of the microheater may 
further comprise the actions of ablation materials present on 
the barrier or physically contacting the microheater in 30 
response to the heat from the microheater. To form a 
micropore with the diameter and depth desired for a particular 
intended use, one or more activations may be necessary, and 
is also dependent on the barrier properties of the barrier. 
An aspect of the present invention contemplates micro- 35 
heater components that are activated one or more times by a 
handheld power supply component, disposing of the first 
microheater component and replacing it with a second micro-
heater component which can then be activated by the original 
handheld power supply component. The present invention 40 
alters the way drugs are delivered. Given the many advan-
tages of transdermal patch delivery--e.g., control of drug 
delivery rate, self-administration, non-invasive delivery, high 
patient compliance-the devices and methods of the present 
invention can, in many cases, replace hypodermic needles 45 
currently used to inject drugs, and is especially useful for 
delivery of proteins, nucleic acids and other biotechnology-
derived compounds. Inherent to the current invention is that 
the drug or active agent reservoir remains outside the body 
and the drug or active agent is transported into the body 50 
through micropores. This gives patients and careproviders 
greater flexibility to interact with and modulate the delivery 
device, or even remove it if needed. Moreover, the present 
invention has flexibility in that the materials used and their 
sterility are not subject to the same safety constraints as for 55 
implants, injections, or pills. 
Methods and devices for creation of micropores in the skin 
have utility beyond drug delivery. As disclosed herein, fluid 
and analytes can be extracted out of the skin for minimally 
invasive monitoring of drugs, disease markers, glucose, and 60 
other metabolites. Micropores also provide conduits for low-
resistance electrical flow for gel-free monitoring of vital sig-
nals or therapeutic electrical stimulation. 
The wireless devices of the present invention also have 
capabilities that can impact medicine. For example, such 65 
devices provide non-invasive skin microablation using a 
power source isolated from the skin. The wireless heating 
tion between the device and a remote microprocessor that 
could control device operation, which may be in conjunction 
with input from biosensors or other sources. Wireless activa-
tion also lends itself to controlling delivery from a device 
injected or implanted in the body. Drug release can be 
remotely controlled for spatial or temporal targeting in an 
actively controlled manner that is mostly non-invasive. 
The present invention comprises methods, devices and sys-
tems for thermal treatments of barriers to increase the perme-
ability of the barrier, and to reduce the barrier properties of the 
barrier. Thermally altering the components of the barrier or 
providing micropores in the barrier can increase the perme-
ability and reduce the barrier properties of the barrier. Such 
thermal treatments may be used alone or as a pretreatment 
step, or in conjunction with other activities. In the methods, 
devices and systems disclosed herein, a barrier can be a solid 
structure interposed between two areas, and an example is a 
bladder, a membrane, a diaphragm, mucous membranes, 
organ covering membranes, outer skin, outer layers of organ-
isms, or industrial or mechanical barriers. Thermal treatment 
devices useful in the methods and systems disclosed herein 
comprise a unitary device where the microheater component 
is in electrical wire connection with the power supply com-
ponent, and the power supply component activates the micro-
heater component by ohmic heating; or may be a wireless 
device and the microheater component is separate from the 
power supply component, and the power supply component 
activates the microheater component by inductive heating. 
Ablation material or materials useful in the methods, devices 
and systems described herein comprise liquids, gels, solu-
tions, multiphase materials, or solids, comprising hydropho-
bic liquids, hydrophilic liquids, water, ethanol, methanol, 
organic compounds, alcohols, ketones, aldehydes, amines, 
ethers, esters, oils, paraffins, fatty acids, salt hydrates, includ-
ing but not limited to calcium hydrates, sodium sulphate 
decahydrate, sodium phosphate dodecahydrate, calcium 
chloride hexahydrate and sodium thiosulfate pentahydrate, 
mixtures or combinations. Such ablation materials may or 
may not be present or be used in the methods, devices and 
systems disclosed herein. Microheaters useful in the devices, 
methods and systems disclosed herein comprise a disk, a 
cone, a donut, a hollow post, or loop, from less than 1 micron 
to hundreds of microns in length. The microheater may be 
made of a single type of metal, layers of metals, conductive 
oxides, conductive polymers or alloys, nickel, nickel-iron, 
ferromagnetic materials, copper, NiCu, PdCo, gadolinium-
silicon-germanium alloy, aluminum, ceramic materials, elec-
trodeposited or vapor-deposited gold, platinum, or palladium 
outer layer coating of nickel, nickel-iron, a magnetic stainless 
steel-type alloy, 400-series alloy, indium tin oxide, lanthanum 
strontium cobalt oxide, and aluminum doped zinc oxide. 
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A method for increasing the permeability of a barrier com-
prises applying an effective amount of an ablation material to 
18 
increase its volume; increasing the permeability of the bar-
rier; and allowing the device to contact the barrier for a 
sufficient amount of time for the transfer of an effective 
amount of one or more active agents from the patch to the 
surface of the barrier. 
A method of increasing the permeability of a barrier for 
sampling a fluid contained by the barrier comprises contact-
ing a selected site on the surface of a barrier with a thermal 
treatment device comprising a microheater component com-
a selected site on the surface of a barrier; providing a thermal 
treatment device comprising a microheater component com-
prising at least one microheater to the selected site on the 
surface of a barrier so that the ablation material is disposed 
between a tip end of the microheater and the surface of the 
barrier; activating the microheater component comprising at 
least one microheater with a power supply component; heat-
ing the ablation material to a temperature sufficient to 
increase the volume; and increasing the permeability of the 
barrier. Another method for increasing the permeability of a 
barrier comprises providing to a selected site on a barrier 
surface, a device comprising a microheater component com-
prising at least one microheater comprising an ablation mate-
rial, activating the microheater component comprising at 
least one microheater comprising an ablation material with a 
power supply component; heating the ablation material to a 
temperature sufficient to increase the volume; and 
increasing the permeability of the barrier.A thermal treatment 
device of the present invention comprises a microheater com-
ponent comprising at least one microheater comprising a 
thermal member having a base end and a tip end; an ablation 
material in contact with the microheater; and a power supply 
component for activating at least one microheater of the 
microheater component. A microheater of the present inven-
tion comprises a thermal member comprising a base end and 
10 prising at least one microheater having an ablation material in 
physical contact with the microheater, and a means for sam-
pling a fluid; activating the microheater component compris-
ing at least one microheater, with a power supply component 
so as to heat the ablation material to a temperature sufficient 
15 to increase its volume; increasing the permeability of the 
barrier; and sampling a fluid released by the barrier. A sam-
pling or collecting method may further comprise detecting, 
monitoring, or analyzing an analyte in the sample, an analyte 
is any chemical or biological material or compound which 
20 may be measured, determined, monitored, and/or analyzed in 
order to gain information, or determine the status, related to 
the object or organism that is the source of the analyte. The 
present invention comprises systems comprising a system for 
transdermal delivery comprising, a thermal treatment device 
a tip end; and an ablation material in physical contact with the 
thermal member. 
25 comprising a microheater component comprising at least one 
microheater having an ablation material in physical contact 
with the microheater, and a transdermal patch comprising at 
least one active agent; and a power supply component to 
activate the microheater component so as to heat the ablation 
30 material to a temperature sufficient to increase its volume. The present invention comprises a method oftransdermal 
delivery of an active agent, comprising, contacting a selected 
site on a surface of skin or a membrane of a human or animal 
with a thermal treatment device comprising a microheater 
component comprising at least one microheater having an 
ablation material in physical contact with the microheater, 35 
and a transdermal patch comprising at least one active agent; 
activating the microheater component comprising at least one 
microheater and a transdermal patch, with a power supply 
component so as to heat the ablation material to a temperature 
sufficient to increase its volume; increasing the permeability 40 
of the surface of the skin or membrane; and allowing the 
device to contact the barrier for a sufficient amount of time for 
the transfer of an effective amount of one or more active 
agents from the transdermal patch to the surface of the skin. 
Another method of transdermal delivery of an active agent 
comprises, contacting a selected site on the surface of skin or 
It must be noted that, as used in this specification and the 
appended claims, the singular forms "a", "an", and "the" 
include plural referents unless the context clearly dictates 
otherwise. 
All patents, patent applications and references included 
herein are specifically incorporated by reference in their 
entireties. 
It should be understood, of course, that the foregoing 
relates only to exemplary embodiments of the present inven-
tion and that numerous modifications or alterations may be 
made therein without departing from the spirit and the scope 
of the invention as set forth in this disclosure. 
Although the exemplary embodiments of the present 
invention are provided herein, the present invention is not 
45 limited to these embodiments. There are numerous modifica-
tions or alterations that may suggest themselves to those 
skilled in the art. a membrane of a human or animal with a thermal treatment 
device comprising a microheater component comprising at 
least one microheater having an ablation material in physical 
contact with the microheater; activating the microheater com-
ponent comprising at least one microheater, with a power 
supply component so as to heat the ablation material to a 
temperature sufficient to increase its volume; increasing the 
permeability of the surface of the skin; removing the micro-
heater component; and applying a transdermal patch com-
prising at least one active agent to the selected site for a 
sufficient amount of time to transfer an effective amount of 
one or more active agents from the transdermal patch to the 
surface of the barrier. A method of delivery of an active agent 
across a barrier comprises contacting a selected site on the 60 
surface of a barrier with a thermal treatment device compris-
ing a microheater component comprising at least one micro-
heater having an ablation material in physical contact with the 
microheater, and a patch comprising at least one active agent; 
activating the microheater component comprising at least one 65 
microheater and a patch, with a power supply component so 
as to heat the ablation material to a temperature sufficient to 
The present invention is further illustrated by way of the 
examples contained herein, which are provided for clarity of 
50 understanding. The exemplary embodiments should not to be 
construed in any way as imposing limitations upon the scope 
thereof. On the contrary, it is to be clearly understood that 
resort may be had to various other embodiments, modifica-
tions, and equivalents thereof which, after reading the 
55 description herein, may suggest themselves to those skilled in 
the art without departing from the spirit of the present inven-
tion and/or the scope of the appended claims. 
EXAMPLES 
Example 1 
The hollow post type microheater was fabricated as fol-
lows. Photosensitive epoxy polymer SUS (Microchem, New-
ton, Mass., USA) was patterned to form an array of posts on 
a dummy substrate (glass, 2"x3"xl mm, Dow Coming, Mid-
land, Mich., USA) and an electroplating seed layer of Ti/Cu 
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of the heating element. The rapid heat response is expected to 
offer a steep thermal gradient across the stratum corneum, so 
that any unnecessary heat effect to the viable skin could be 
minimized. A simulated induction power density for the 
cross-section of a microheater at 342 kHz indicated that non-
uniform heating power generation due to the non-uniform 
eddy current distribution for the given geometry was present. 
The outer perimeter of the post generated more power than 
the inner perimeter. 
was deposited on it using a DC sputterer (CVC DC sputterer, 
CVC, USA). Polymethylmethacrylate solution (PMMA, 
Microchem, Newton, Mass., USA) was applied to the posts. 
Reactive ion etching (RIE) was performed to expose the top 
portion of the posts using a reactive ion etcher (Plasma-
Therm RIE, Plasma-Therm, ST. Petersburg, Fla., USA), and 
the exposed seed layer was removed by wet-etching (sulfuric 
acid (10 ml)+H2 0 (100 ml) and hydrofluoric acid (5 ml)+H20 
(100 ml). The remaining PMMA was removed by an organic 
10 
solvent (ethyl lactate) rinse. Nickel was electroplated on the 
Example 3 seed layer, and the protruding SUS was polished away. Poly-
dimethylsiloxane (PDMS, Dow corning, Midland, Mich., 
USA) is applied evenly to the structure. Again, RIE was 
performed to reveal the tip of the electroplated posts using a 15 
reactive ion etcher (Plasma-Therm RIE, Plasma-Therm, St. 
Petersburg, Fla., USA). Finally the entire microheater array 
was released from the dummy glass substrate. The micro-
heater array was formed as a 20x20 array of hollow posts with 
The microheaters of the present invention, one with a cone 
shape and one with the hollow posts, were applied to an 
in-vitro skin ablation experiment. FIG. 10 is a photomicro-
graph and FIGS. lla and llb is a scanning electron micro-
graph (SEM) of human cadaver skin (stratum corneum and 
epidermis) after the microheaters were applied to the skin, 
activated and removed. Two sites oflocal skin micro-ablation 
in the position of the conical tips andan array of donut-shaped 
openings in the shape of the tips of the hollow posts are shown 
a base plate. Both the hollow posts and the base plate were 20 
made of electroplated nickel. 
Example 2 
The induction heating performance of the fabricated hol-
low post array of EXAMPLE 1 has been characterized while 
applying an AC magnetic field with the excitation coil. Liquid 
crystal polymer (LCP) paper, which changes its color perma-
nently when a temperature exceeds pre-set temperatures of 
110, 121or161° C., was used as a temperature indicator for 
initial studies. The hollow post array was placed on top of the 
temperature indicator papers inside the coil, and an AC cur-
rent of controlled duration ( 0 .05 second increment) and speci-
fied frequency was applied to the coil. The resulting tempera-
ture data is shown in FIG. 9. The excitation time was recorded 
when each LCP paper changed color. Therefore, the x axis of 
graph represents the minimum time required to achieve the 
given temperature (the y axis). The RMS magnetic field 
applied to the heating element was approximately 50 auss at 
frequencies of282 and 342 kHz. Since eddy current loss in the 
micro-heating element increases with applied frequency, the 
higher frequency excitation produced higher temperature 
than lower frequency as expected. It is believed that the tem-
perature needed for thermal ablation of skin is approximately 
109° C., it can be concluded that the prototype hollow post 
array can microablate skin. The marks on the paper mimicked 
the pattern of the posts, indicating the localized heat pattern 
representative of the ring-shaped tip of the posts. 
Finite element analysis (FEA) was performed to estimate 
induction heating power of the microheaters from 
EXAMPLE 1 for the multiple frequencies, using ANSYS 
Emag 7 .1. Three-dimensional simulation was performed for a 
quarter portion of the single post section. The simulation 
parameters and simulated results are given in Table 1. 
TABLE 1 
Relative permeability of NI 
Electrical resistivity of NI (Q · m) 
Average power density at 282 kHz (W/m3 ) 
Average power density at 342 kHz (W/m3 ) 
Average power density at 1 Mhz (W/m3) 
100 
0.69 x 10 7 
0.37 x 109 
0.52 x 109 
2.7 x 109 
The results indicated that average power density (APD) of the 
342 kHz excitation was 1.4 times larger than that of282 kHz. 
Also, it was estimated that if the excitation frequency 
increased to 1 MHz, the APD increased to almost 5 .2 times 
that at 342 kHz, which provides a rapid temperature response 
in FIGS. 10 and lla and llb, respectively. The fabricated 
microheaters created localized micro-ablation in human skin. 
To simulate an in-vivo experiment, the conical microheater 
25 was applied and energized on the skin of a hairless rat imme-
diately after death. The skin specimen was then removed and 
prepared for sectioning using a cryostat microtome. As shown 
in FIG. 12, the skin was indented due to pressing the cone-
shaped microheater against the skin, and the stratum corneum 
30 was ablated along the surface of the indention. 
Other methods can be used to measure effects of micro-
heater treatment of skin. After exposure to thermal treatment 
by the present invention, skin can be examined histologically 
to determine the location and extent of ablation, as indicated 
35 by structural changes and darkened tissue color. The skin is 
fixed and sectioned with a cryostat microtome at a thickness 
of 10-14 µm. Skin slices are stained with hematoxalyn and 
eosin and cross-sectional images are collected by digital 
microscopy (Olympus). Using image analysis software (Im-
40 agePro Plus), the depth, width and total area of microablation 
is quantified for correlation with other experimental measure-
ments and model predictions. 
To determine the temperature profile in skin during microa-
blation, a series of temperature-sensitive dyes (Licristal, 
45 Hallcrest) that can label the skin and undergo permanent color 
change ifthe temperature exceeds different threshold values 
can be used. Contour lines of peak temperatures in skin can be 
mapped and directly correlated with changes in histological 
features. An infrared camera for microscopic examination of 
50 the skin during microablation can be used to obtain kinetic 
information, but spatial information is limited primarily to the 
x-y axis parallel to the skin surface, with difficulty obtaining 
z-axis information into the depth of skin. Temperature pro-
files generated from these data are compared to histological 
55 data as well as predictions from theoretical models. The nega-
tive control can be skin contacted with non-activated heating 
elements and the positive control can be skin heated to various 
temperatures on a controlled hot plate. 
60 Example 4 
Microheater components are tested for use in ablation of 
stratum corneum and increasing barrier permeability and 
increased drug transport by assessing transport across 
65 cadaver skin by three different molecules. Calcein is a low 
molecular weight ( 623 Da) fluorescent molecule used to mea-
sure skin permeability by spectrofluorimetric assay and 
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image transport pathways in skin by confocal microscopy. 
BSA (bovine serum albumin) (66 kDa) is a macromolecular 
protein that can be fluorescently labeled and used as a mac-
romolecular companion to calcein to probe the effect of 
molecular size. Insulin is a polypeptide (6 kDa) that will be 
used for comparison with in vivo studies involving insulin 
delivery to diabetic rats. To perform skin permeability mea-
surements, cadaver epidermis is placed in a Franz diffusion 
cell at 3 7° C. and an array of microheaters is then positioned 
on the stratum comeum side and thermally activated to cause 10 
microablation. The lower, receptor compartment is filled with 
5 ml of well-stirred phosphate buffer saline, the receptor 
solution, and the upper, donor compartment is filled with a 
model drug solution. Every hour, or more frequently, 1 ml of 15 
receptor solution is sampled, and replaced with fresh saline, 
and fluorescence intensity is measured using calibrated spec-
trofluorometry and analyzed to determine rates of transder-
mal delivery. The micropores made by the activation of the 
microheaters are effective in reducing the barrier capability of 20 
the cadaver skin. Calcein, BSA and insulin, added individu-
ally to the donor compartment, are later measured in the 
receptor solution. 
22 
Example 6 
Fabrication of Excitation Coils with AC Power Source. 
An excitation coil is needed to create magnetic fields that 
wirelessly activate the inductive microheaters. When the 
power supply component is placed above the skin and around 
the microheaters, the inner diameter of the coil must be large 
enough to contain the microheaters inside. In preliminary 
experiments, 1 cm inner diameter coil size was chosen that 
was suitable for initial heating experiments. The excitation 
coil was fabricated by hand-winding 100 turns of thin mag-
netic wire on a short epoxy tube. The coil was connected to a 
conventional AC power supply and when tested with AC 
current over the range of 1-2 A, it showed stable operation. 
Other considerations for coil construction include the fol-
lowing. The excitation coil will be fabricated by convention-
ally winding conductor coils on optimally-shaped hollow 
polymer cores, optionally with incorporation of flux-guiding 
magnetic material. Coils are made with inner diameters of 1 
cm, 3 cm, and 5 cm; cylinder height of 5 mm; 100 and 200 
turns; and diameters of conductor wires 50 µm and 150 µm. 
The inner diameter of the coils may affect power supply 
characteristics. Multiple turn coils allow a tradeoffbetween 
Example 5 
Drug Delivery In Vivo. 
25 current and wire length for a given magnetic flux generation, 
but have the potential for introduction of unwanted parasitics 
(e.g., conductor resistance or coil self-resonance) that could 
deleteriously affect efficiency or operation of the excitation 
The in vivo skin model is a Sprague-Dawley hairless rat, a 
30 
commonly used model for human skin permeability due to 
the similarity of hairless rat and human skin. For initial stud-
ies, rats ARE anesthetized by intraperitoneal injection of ure-
thane (1000 mg/kg) and treated with a thermal treatment 
device of the present invention. The skin is exposed either 35 
briefly to a blue tissue marking dye to visualize the size and 
coil. Variation of wire diameter allows determination of opti-
mal conductor thickness, which could be a function of fre-
quency due to the well-known skin effect limiting the efficacy 
of thick conductors in the MHz and higher frequency 
regimes. 
Additional design constraints to be considered in the exci-
tation coil system are size, frequency, and coil current. Off-
the-shelfbattery powered DC-AC switching inverters and RF 
amplifiers that are packaged and interconnected using con-
ventional miniaturized printed circuit board technology can 
location of pores, or exposed for over an hour to a calcein 
solution to image the transdermal transport process. After 
sacrificing the animal, skin specimens are excised and pre-
pared for histological examination by cryostat sectioning. 
The skin from rats exposed to blue dye and skin from rats 
exposed to the calcein solution both show transport of the 
molecules into the micropores and with time, transport across 
the epidermis of the tissue sections. 
40 be utilized to produce the required time-varying coil currents. 
45 
For insulin delivery studies, rats are made diabetic by intra-
venous injection with 100 mg/kg streptozotocin, which pro-
duces diabetes the next day due to destruction of pancreatic 
islet cells. Under urethane anesthesia, skin is treated with a 50 
thermal treatment device of the present invention and the 
treated skin area is exposed to an Humulin-R insulin solution. 
Blood samples are collected by tail veil laceration overtime to 
measure glucose concentration using a FreeStyle glucose 
monitor to determine pharmacodynamic response and to 55 
measure insulin concentration by radioimmunoassay to 
determine pharmacokinetic response, after which the animal 
is sacrificed. Control experiments include placement of insu-
lin on skin which does not receive treatment using a thermal 
treatment device of the present invention, use of a thermal 60 
treatment device of the present invention with a saline solu-
tion instead of an insulin solution, no treatment, and intrad-
ermal injection of known amounts of insulin ranging from 10 
mU to 10 U for calibration. Rats that received insulin through 
micropores made with a thermal treatment device of the 65 
present invention show insulin in the blood and response to 
glucose control. 
It should be noted that as in most magnetic systems, although 
currents are reasonably high (order 1 A), the voltages are low 
( <10 V), which maintains overall system safety. 
Example 7 
Computer Simulation for Thermal Analysis of Skin Heating 
Computer simulation using ANSYS software was used to 
model heat flows generated directly in heating elements and 
skin, as well as thermal diffusion from heating elements to 
skin and a neighboring drug reservoir. Safe and painless ther-
mal microablation of skin requires delicate control of heat 
generation and transfer to ablate stratum corneum without 
damaging either deeper tissues or an active agent stored in the 
patch. To investigate the heat transfer properties through skin, 
a finite element thermal simulation was performed. FIG. 13 
shows a schematic model of a metal heating element array 
attached to a drug-containing patch above and to skin below. 
Each heating element has a width w= 100 µm, a height h= 100 
µm, and a space s=300 µm between neighboring elements. 
The thickness of epidermis is tep,=80 µm and that of dermis 
tderm =2 mm. Thermal properties of skin and other major 
materials used for the simulation are summarized in Table 2. 
For this preliminary temperature profile analysis, the energet-
ics associated with phase transitions of water and other skin 
tissue components was not taken into account (a conservative 
assumption). 
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TABLE2 
Material Properties used for simulation of temperature profiles 
Thermal 
conductivity Specific heat 
[W/m·K] [J/Kg· K] Density [Kg/m3 ] 
Epidermis 0.24 3590 1200 
Dermis 0.45 3300 1200 
Metal(Ni) 90.7 444 8900 
24 
A. Zahar, "Transdermal drug delivery and analyte extrac-
tion," 2004, U.S. Pat. No. 6,711,435 
S. Zinn and S. L. Semiatin, Elements of Induction Heating, 
Electric Power Research Institute, Palo Alto, Calif., 1988 
J. Lammeraner, and M. Stafl, Eddy current, London: Iliffe 
Books Ltd., 1966, Chapter 2 
J. A. Eppstein, M. R. Hatch, and D. Yang, "Microporation of 
human skin for drug delivery and monitoring applica-
tions," 2000, U.S. Pat. No. 6,142,939 
Thermal insulation 0.03 
Air 0.025 
1090 1420-
1040 0.616 
10 E. W. Smith, et al., Percutaneous Enhancers, CRC Press, 
Boca Raton, Fla., (1995). 
Four points (labeled 1, 2, 3, and 4) were selected for tem-
perature examination as shown in FIG. 13. Points 1, 2, and 3 
are located at the interface between the microheater and the 15 
epidermis layer 370, between epidermis and dermis 380, and 
approximately 200 µm below epidermis, respectively. The 
insulation or thermal barriers 350 and the patch 360 contain-
ing an active agent 280 are shown Nerves are considered to 
exist at Point 3 and below. Point 4 is located approximately 20 
200 µm above the heating elements within the patch drug 
matrix. The skin surface temperature needed for thermal abla-
tion of skin is approximately 130° C., while the minimum 
temperature for nerve stimulation is approximately 40-50° C. 
The temperature range at which drugs might be damaged 25 
depends strongly on the type of drug. µm 
Given the constraints outlined above, we found that a 
microheater operating at 100 mS for 70 ms may be effective. 
As shown in FIG. 14, the temperature at point 2 reaches 130° 
C. in 70 ms while that of point 3 and 4 stay below 50° C. and 30 
80° C., respectively. Consistent with literature findings, opti-
mized conditions can microablate stratum comeum while 
protecting viable skin and drugs. 
Thermal profiles in skin due to direct heating by magnetic 
field were simulated to be sure that the magnetic fields applied 35 
by the excitation coil only heat the microheaters, which in 
turn heat the skin, and do not have any direct effect on the skin 
which might cause uncontrolled heating in undesirable loca-
tions. A finite element analysis of eddy (inductive heating) 
current usingANSYS magnetic software was performed. The 40 
simulation model consists of a heating element, skin, and air. 
It was found that the eddy current vector is generated only on 
the heating element, not on the skin itself. Since there is no 
eddy current present in the skin, no inductive heating will be 
generated inside the skin. Since the frequency utilized for 45 
inductive heating is several orders of magnitude lower than 
the GHz/microwave frequencies associated with excitation of 
rotational modes of water, no heating is expected, nor was any 
observed, from this mechanism. 
R. L. Bronaugh, et al., Percutaneou Absorption:Drus, Cos-
metics, Mechanisms, Methodology, Marcel Dekker, NY, 
992, (1999). 
What is claimed is: 
1. A method for increasing the permeability of a barrier, 
comprising the steps of: 
a) applying an effective amount of an ablation material to a 
selected site on a surface of a barrier; 
b) providing a thermal treatment device including a micro-
heater component having at least one microheater, and 
positioning the thermal treatment device relative to the 
surface of the barrier; 
c) energizing the at least one microheater of the micro-
heater component with a power supply component, 
wherein the power supply component is separate from 
the thermal treatment device and energizes the micro-
heater component by creating a wireless magnetic field 
that interfaces between the power supply component 
and the microheater component; and 
d) heating the ablation material to a temperature from 
greater than 100° C. to about 200° C. to induce a phase 
change in the ablation material, thereby increasing the 
volume of the ablation material which is effective to 
ablate the surface of the barrier thereby increasing the 
permeability of the barrier. 
2. The method of claim 1, wherein the barrier is selected 
from the group consisting of human skin, animal skin and 
mucous membrane. 
3. The method of claim 1, wherein the ablation material is 
selected from the group consisting of liquids, gels, solutions, 
multiphase materials, and solids. 
4. The method of claim 1 wherein the geometric configu-
ration of the microheater is selected from the group consisting 
of a disk, a cone, a donut, a hollow post, and a loop, all of 
which range from less than 1 micron to hundreds of microns 
in length. 
5. The method of claim 1, wherein the microheater is 
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wireless magnetic field that interfaces between the 
power supply component and the microheater compo-
nent; and 
c) heating the ablation material to a temperature from 
greater than 100° C. to about 200° C. to induce a phase 
change in the ablation material, thereby increasing the 
volume of the ablation material which, in tum, ablates 
the surface of the barrier thereby increasing the perme-
ability of the barrier. 
7. A thermal treatment device, comprising: 
a) a microheater component including at least one micro-
heater having a thermal member including a base end 
and a tip end; 
b) an ablation material in contact with the microheater, 
wherein a volume of the ablation material increases 
upon heating the ablation material to a temperature from 
greater than 100° C. to about 200° C. to induce a phase 
change within the ablation material; and 
c) a power supply component which is configured to acti-
vate the at least one microheater of the microheater 
component, wherein the power supply component is 
separate from the microheater component and activates 
the microheater component by creating a wireless mag-
netic field that interfaces between the power supply 
component and the microheater component. 
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8. The device of claim 7, wherein the ablation material is 
selected from the group consisting of liquids, gels, solutions, 
multiphase materials, and solids. 
9. The device of claim 7, wherein the ablation material 
contacts an open space area of the microheater. 
10. The device of claim 7, wherein the ablation material 
contacts a tip end of the microheater. 
11. The device of claim 7, wherein the geometric configu-
ration of the microheater is selected from the group consisting 
10 
of a disk, a cone, a donut, a hollow post, and a loop, all of 
which range from less than 1 micron to hundreds of microns 
in length. 
12. The device of claim 7, wherein the microheater is 
15 selected from the group consisting of single type metals, 
layers of metals, conductive oxides, conductive polymers or 
alloys, nickel, nickel-iron, ferromagnetic materials, copper, 
NiCu, PdCo, gadolinium-silicon-germanium alloy, alumi-
num, ceramic materials, electrodeposited or vapor-deposited 
20 gold, platinum, or palladium, outer layer coatings of nickel or 
nickel iron, magnetic stainless steel-type alloy, 400-series 
alloy, indium tin oxide, lanthanum strontium cobalt oxide, 
and aluminum doped zinc oxide. 
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